Wealth Alliance Acquires 217 Shares of Hologic, Inc. (NASDAQ:HOLX)

Wealth Alliance boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,739 shares of the medical equipment provider’s stock after purchasing an additional 217 shares during the quarter. Wealth Alliance’s holdings in Hologic were worth $410,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic during the 4th quarter worth about $27,000. Venturi Wealth Management LLC bought a new stake in Hologic during the 3rd quarter worth about $29,000. NBC Securities Inc. bought a new stake in Hologic during the 3rd quarter worth about $33,000. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Hologic during the 4th quarter worth about $33,000. Finally, Deseret Mutual Benefit Administrators grew its position in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 155 shares during the period. 94.73% of the stock is owned by institutional investors.

Insider Transactions at Hologic

In other news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock worth $2,473,443 in the last 90 days. Corporate insiders own 1.75% of the company’s stock.

Hologic Trading Down 0.3 %

NASDAQ HOLX opened at $74.92 on Thursday. The stock has a market capitalization of $17.59 billion, a price-to-earnings ratio of 35.51, a PEG ratio of 2.54 and a beta of 1.00. The stock’s 50 day moving average price is $75.68 and its two-hundred day moving average price is $72.48. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $87.88.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.07 EPS. As a group, analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HOLX. UBS Group boosted their target price on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. William Blair restated an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, Raymond James boosted their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.